Thanks to their glucose-lowering and weight loss effects, incretin analogs were first approved for the treatment of type 2 diabetes mellitus (T2D) and subsequently for chronic weight management in people with obesity or overweight associated with at least one weight-related comorbidity [3]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.